Clinical Trials Browser

Interventional × capivasertib × Genitourinary × Clear all

NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04493853 2026-05-05

CAPItello-281

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT05593497 2026-03-27

SNARE

Phase 2 Recruiting

Prostatic Neoplasms

NCT03903835 2025-04-09

ProBio

Phase 3 Recruiting

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT05348577 2025-01-27

CAPItello280

Phase 3 Active not recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT03310541 2023-05-06

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Phase 1 Completed

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04087174 2022-07-13

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Phase 1 Completed

Neoplasm Metastasis, Prostatic Neoplasms

NCT02121639 2022-05-05

ProCAID

Phase 1/2 Completed

Prostatic Neoplasms

NCT04712396 2021-04-09

A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

Phase 1 Completed

BreastGenitourinary

Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)

NCT02525068 2018-08-08

RE-AKT

Phase 2 Unknown

Adenocarcinoma of the Prostate